Deep Track Capital ACLX Position
Exited5-Fund ConvergenceDeep Track Capital exited their position in Arcellx Inc. (ACLX) in Q1 2024, after holding the stock for 2 quarters.
The position was first reported in Q4 2023 and has been tracked across 2 quarterly 13F filings.
ACLX is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for anitocabtagene-autoleucel in 259 days (Dec 31, 2026), making the timing of Deep Track's position particularly relevant.
Short interest stands at 10.9% of float with 1.0 days to cover, indicating significant bearish positioning against the stock.
About Arcellx Inc.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Full company profile →Short Interest
10.9%
1.0 days to cover
Deep Track Capital ACLX Position History
Frequently Asked Questions
Does Deep Track Capital own ACLX?
No. Deep Track Capital exited their position in Arcellx Inc. (ACLX) in Q1 2024. They previously held the stock for 2 quarters.
How many hedge funds own ACLX?
5 specialist biotech hedge funds currently hold ACLX, including Perceptive Advisors, RA Capital Management, Cormorant Asset Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy ACLX?
Deep Track Capital's position in ACLX was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's ACLX position increasing or decreasing?
Deep Track Capital completely exited their ACLX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ACLXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →